Segesterone Acetate
- TRADE NAME: Annovera (in combination with ethinyl estradiol) (The Population Council Inc)
- INDICATIONS: Indicated for use by females of reproductive potential to prevent pregnancy.
- CLASS: Progestin/estrogen CHC
- HALF-LIFE: 4.5 hours
FDA APPROVAL DATE: 08/10/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
no increased risk of genital or nongenital birth defects.
CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric